Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MISTRAL: Early vs Late Abciximab in STEMI
NCT00638638Phase 3Unknown
- Sponsor
- Strasbourg University Hospital
- Start
- Jan 2005
- Primary completion
- Aug 2009
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abciximab in myocardial infarction (MI) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: ST segment regression 1 hour after angioplasty. Status: unknown.
02
Drugs
abciximab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT00638638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00638638.